Inmune Bio (INMB) Equity Average (2018 - 2025)
Historic Equity Average for Inmune Bio (INMB) over the last 8 years, with Q3 2025 value amounting to $27.1 million.
- Inmune Bio's Equity Average fell 2763.09% to $27.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $27.1 million, marking a year-over-year decrease of 2763.09%. This contributed to the annual value of $34.7 million for FY2024, which is 2874.16% down from last year.
- Per Inmune Bio's latest filing, its Equity Average stood at $27.1 million for Q3 2025, which was down 2763.09% from $29.3 million recorded in Q2 2025.
- In the past 5 years, Inmune Bio's Equity Average registered a high of $84.2 million during Q4 2021, and its lowest value of $27.1 million during Q3 2025.
- In the last 5 years, Inmune Bio's Equity Average had a median value of $51.2 million in 2021 and averaged $50.4 million.
- In the last 5 years, Inmune Bio's Equity Average surged by 14220.95% in 2021 and then plummeted by 4318.54% in 2024.
- Quarter analysis of 5 years shows Inmune Bio's Equity Average stood at $84.2 million in 2021, then dropped by 26.51% to $61.9 million in 2022, then plummeted by 34.36% to $40.6 million in 2023, then fell by 12.92% to $35.4 million in 2024, then decreased by 23.35% to $27.1 million in 2025.
- Its Equity Average was $27.1 million in Q3 2025, compared to $29.3 million in Q2 2025 and $30.9 million in Q1 2025.